Estrogen receptor (Erα) status has become widely used as a key predictive biomarker of potential responsiveness to endocrine therapy in breast cancer. Positive receptor status predicts a positive outcome to endocrine therapy. This includes both estrogen analogue (including Tamoxifen) therapy and aromatase inhibitor therapy.
It was subsequently learned that the phosphorylation status of Erα provides an improved predictive tool for breast cancer responsiveness to endocrine therapy.
The Murphy technology provides an improved predictive tool is based on single- and multi-variate analysis of the specific pattern of phosphorylation at 7 epitopes. This provides:
· A diagnostic tool to determine the best type of therapy for a given breast cancer patient.
· A tool to assist in the evaluation of SERM or aromatase inhibitor drugs for breast cancer.
Figure 1. Multiple phosphorylation sites on Erα
Figure 2. Phosphorylation epitope immunohistochemical stain of breast cancer cell nuclei. Figure 3. Relative death or recurrence rates of in patients with positive and negative phosphorylation at one of the epitpes.
For more information download the Tech-op here
Tech ID
Inventors
Patent Status
License Status
80.02.758
Dr. Leigh Murphy, et al
Biochemistry & Medical Genetics
University of Manitoba
Provisional patent :61/251,690
Worldwide, exclusive
This patent portfolio is available for licensing to qualified development partners.